For about twenty years now, biologists have known that a small number of specific proteins can take a fully-developed adult cell — a skin cell, a kidney cell, a fully-specialized worker bee of a cell that has spent its working life doing one specific job — and send it backward in developmental time, all the way back to the embryonic state from which it originally came. The phenomenon is real, repeatable, and won Shinya Yamanaka of Kyoto University the 2012 Nobel Prize in Physiology or Medicine for the discovery. The four proteins involved — known thereafter as the Yamanaka factors — function in the lab as a kind of factory-reset button for any vertebrate cell, capable of stripping away decades of acquired identity and aging signatures and returning the cell to a younger, more flexible state. The procedure works on cells in petri dishes. It works on mice. It works on non-human primates. What no one had yet attempted, until January 2026, was to apply it to a living human being.
According to MIT Technology Review’s coverage of the announcement, the FDA in January 2026 granted Investigational New Drug clearance to Life Biosciences, a Boston-based biotech founded on the research of Harvard Medical School professor David Sinclair, to begin a Phase 1 clinical trial of an experimental therapy called ER-100. The trial will enrol patients with two age-related forms of optic nerve damage — glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION) — and will deliver, via injection into the eye, a modified adeno-associated virus carrying the genes for three of the four Yamanaka factors. The genes will remain inactive in the patient’s cells until the patient takes an oral dose of doxycycline, which switches them on. Once activated, the proteins are expected to partially reset the epigenetic markers of the patient’s optic nerve cells, restoring them to a younger configuration without erasing the underlying identity that makes them optic nerve cells in the first place. If it works, the patients should regain at least some of the vision they have lost. If it works well, it will demonstrate something more substantial: that cellular aging in living humans is, in principle, reversible.
What partial reprogramming actually is
The original Yamanaka procedure used four transcription factors — OCT-4, SOX-2, KLF-4, and c-Myc — to convert adult cells into induced pluripotent stem cells (iPSCs), which behave essentially like embryonic stem cells and can develop into any tissue type. The conversion is complete: an adult skin cell, after exposure to all four factors, loses its identity as a skin cell and becomes a generic precursor cell that could, in principle, develop into any other cell type in the body. This is what stem-cell biologists call “full reprogramming.” It is extraordinarily useful in the laboratory, where iPSCs can be grown into any tissue of interest for research or transplantation. It is also extraordinarily dangerous in a living body. When all four Yamanaka factors are activated in adult mice, the animals develop teratomas — chaotic tumours containing hair, bone, muscle, and other tissue types — within weeks. The cells lose their identity. The body cannot tolerate it.
The advance that made human trials conceivable was the development of what is called “partial” or “transient” reprogramming. Per Scientific American’s coverage of the underlying science, partial reprogramming limits the exposure to the Yamanaka factors — either by using only a subset of them, or by switching them on for short periods rather than continuously, or both. The goal is to reset the cell’s epigenetic age markers — the chemical tags on its DNA that accumulate with age and govern which genes are switched on or off — without erasing the cell’s underlying identity as a specific type of cell. As reported in BBC Science Focus’s coverage of the broader field, Life Biosciences CEO Jerry McLaughlin describes the company’s approach as operating “in a space called partial epigenetic reprogramming,” in which the chemical tags that control which genes are active and which are silent are selectively rewritten without resetting the cell’s whole identity. A 2020 paper in Nature by Yuancheng Lu, then a graduate student in David Sinclair’s lab, demonstrated this principle in mice by using just three of the four factors (OCT-4, SOX-2, and KLF-4 — excluding c-Myc, which is the one most strongly associated with cancer). The treated mice, whose optic nerves had been deliberately damaged, recovered substantial visual function. Their optic nerve cells had been partially reset to a younger state without losing their identity as optic nerve cells.
Why the eye
The choice of optic nerve disease for the first human trial was deliberate and reflects a careful series of safety calculations. The eye is one of the few organs in the human body that can be treated with a localised injection without the therapy spreading to other tissues. The interior of the eye is partially walled off from the general bloodstream by the blood-retinal barrier, which means that the modified virus carrying the three Yamanaka factor genes stays largely confined to the area where it is injected. If something goes wrong — if cells start dividing inappropriately or losing their identity — the consequences are limited to the eye rather than spreading through the body. Vision loss, while serious for the affected patient, is not life-threatening in the way that systemic effects elsewhere in the body could be.
The eye also provides a clear, measurable endpoint. Vision can be quantified objectively — visual acuity, contrast sensitivity, visual field, optic nerve thickness — in ways that “biological aging” more broadly cannot. If ER-100 restores vision in the trial patients, the result will be unambiguous. If it does not, the result will also be unambiguous. The Phase 1 study is primarily focused on safety and tolerability, which is standard for first-in-human trials of novel gene therapies, but the visual outcomes will provide an early signal of whether the underlying biological premise — that partial epigenetic reprogramming can restore function to aged tissue — translates from mice and monkeys to human beings.
The control mechanism
One of the technical features distinguishing ER-100 from earlier attempts at cellular reprogramming is the use of a doxycycline-inducible switch. The genes carried by the viral vector are placed under the control of a regulatory sequence that responds to doxycycline, a common oral antibiotic. In the absence of doxycycline, the genes remain inactive. When the patient takes a dose of doxycycline, the genes switch on for a limited window of time. When the doxycycline clears the patient’s system, the genes switch off again. The mechanism provides a level of control that earlier cellular reprogramming approaches lacked — if the treatment produces concerning effects, the patient simply stops taking doxycycline, and the activated cellular reprogramming should cease.
The combination of three safety features — local delivery to the eye, exclusion of the most dangerous Yamanaka factor (c-Myc), and the doxycycline-inducible on/off switch — is what convinced the FDA that ER-100 was safe enough to test in humans. As reported in Nature Biotechnology’s coverage of the FDA approval, Life Biosciences’ preclinical work in non-human primates showed that the therapy was well tolerated with no systemic toxicities. Whether the same will be true in human patients, with their longer lifespans and more complex disease backgrounds, is a question the Phase 1 trial is designed to answer.
What this is and what it is not
What ER-100 is not: a proven anti-aging therapy. The Phase 1 trial will involve approximately a dozen patients, will run for one to two years, and is primarily designed to detect safety problems rather than to demonstrate effectiveness. Even if the trial succeeds completely, it will only establish that partial epigenetic reprogramming is safe enough to test in larger Phase 2 and Phase 3 trials, which would themselves take additional years to complete. The pathway from “first human trial” to “approved therapy for general use” typically runs 8 to 12 years for novel drug classes. The trial does not establish that humans can live longer. It does not establish that cellular aging can be reversed in tissues outside the eye. It does not establish that ER-100 will become a routine medical treatment for anything.
What ER-100 is: the first formal attempt, in any human being, to test whether the molecular machinery of cellular reprogramming can be safely applied to living people. The trial follows two decades of laboratory work — Yamanaka’s original 2006 discovery, the subsequent demonstrations in mice and non-human primates, the development of partial reprogramming techniques, the engineering of the doxycycline-inducible viral vector — and it represents the moment at which the underlying science crosses from animal models into human medicine. Several other companies are working on similar approaches; Altos Labs, backed by Jeff Bezos, and Retro Biosciences, backed by Sam Altman, are among the better-known competitors. The Life Biosciences trial is simply the first one to clear the FDA. The next several years will determine whether cellular reprogramming becomes a new category of medicine or remains a laboratory curiosity. The answer will not come immediately, but the experiment is now finally underway in the species the experiment was always ultimately about.
